International Organization For the Study of Inflammatory Bowel Disease

What International Organization For the Study of Inflammatory Bowel Disease does

The International Organization For the Study of Inflammatory Bowel Disease (IOIBD) is a non-profit international medical research organization founded in 1981 and constituted as a Swedish tax-exempt foundation (Stiftelsen for Utbildning och Forskning avseende Inflammatoriska Tarmsjukdomar, "SUFIT") with a wholly-owned Dutch operating subsidiary (IOIBD Institute B.V., founded November 2021). It is the only international worldwide organization exclusively devoted to inflammatory bowel disease, operating an invitation-based active membership capped at 60 leading academic clinicians and scientists drawn from Europe, the United States, Canada, Australia, Hong Kong, Israel, Japan, New Zealand, and emerging-IBD regions.

IOIBD's product surface is a portfolio of member-facing scientific and educational services rather than commercial technology: an Operating Grants program (up to €200,000 per project, with preference for grants ≤€50,000), Travel Grants (up to €20,000 per awardee), the Clinical Experience Exchange Program (USD 60,000 per awardee, USD 120,000 per year, funded by the Helmsley Charitable Trust), the Empowering Women in IBD Leadership Program (launched 2025 with Pfizer), an Annual General Meeting rotated globally (Florence 2024 through Jaipur 2029), a webinar series including seven COVID-19 and IBD sessions since March 2020, peer-reviewed scientific publications and consensus statements (notably STRIDE-II, a Top 10 Most Cited Article in Gastroenterology 2021), and a member portal. Revenue is generated through pharmaceutical and biotechnology partnerships (50+ companies including AbbVie, Amgen, Eli Lilly, Ferring, Gilead, Janssen, MSD, Pfizer, Roche, Sanofi, and Takeda), grants from charitable foundations, and dues-style support, with the Dutch subsidiary acting as the third-party financing vehicle. The organization has no proprietary technology platform and is governed by an elected Executive Committee, a Board of Foundation, and a Scientific Secretariat managed by Executive Director Marischka Konings.

Name

International Organization For the Study of Inflammatory Bowel Disease

Legal name

The International Organisation for the Study of Inflammatory Bowel Disease (IOIBD)

Website

https://ioibd.org

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

IOIBD is a Swedish-based non-profit international medical research organization founded in 1981, uniting the world's leading 60 academic clinicians and scientists to advance inflammatory bowel disease care, education, and research through grants, consensus publications, and global meetings.

Ownership category

akta.pro rank

Product category

Medical Research Organization

NAICS

Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro industry

PRIMARYHLAJAKAN

Global Health Research, Evidence & Technical Assistance Organizations

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

SECONDARYHLAKAEAD

Inflammatory Bowel Disease (IBD) Care

Healthcare & Life Sciences/Specialist Medical Practice/Gastroenterology & Hepatology

SECONDARYBPAGACAA

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)

Business & Public Services/Nonprofit, NGO & Social Services/Health & Medical Nonprofits

Keywords

• Inflammatory bowel disease research
• Medical research grants
• Clinical consensus guidelines
• Gastroenterology scientific meetings
• IBD clinician network

Headquarters

HQ city

Linköping

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales, Technology or R&D

Revenue model

1. Membership-based non-profit organization: IOIBD operates as a Swedish-based non-profit foundation (SUFIT/Stiftelsen for Utbildning och Forskning avseende Inflammatoriska Tarmsjukdomar) exempted from Swedish tax. The organization receives funding from pharmaceutical company partnerships and grants, with net profits from its subsidiary IOIBD Institute B.V. transferred annually to the foundation.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

IOIBD is the only international worldwide organization devoted exclusively to inflammatory bowel disease (IBD), convening an invited membership of up to 60 leading academic clinicians and scientists to advance IBD care, education, and research through global collaboration. It funds research via competitive grant programs (Operating Grants up to €200,000, Travel Grants up to €20,000, and the Clinical Experience Exchange at $60,000 per awardee), produces consensus guidelines and scientific publications, and operates an Annual General Meeting rotating across global venues. The Swedish foundation SUFIT is supported operationally by its wholly-owned Dutch subsidiary IOIBD Institute B.V.

Product overview

IOIBD operates as a professional medical research organization rather than a technology product company. The organization offers a portfolio of membership-based services including the IOIBD Website and Member Portal (the primary digital platform for information and member services), scientific grant programs (Operating Grants up to €200,000, Travel Grants up to €20,000, and Clinical Experience Exchange Program at $120,000/year), educational programs (the Empowering Women in IBD Leadership Program in collaboration with Pfizer), publications and guidelines, webinars including COVID-19 series, and the Annual General Meeting format combining business meetings with satellite scientific sessions. The IOIBD Institute B.V. (founded 2021) is a Dutch subsidiary supporting third-party financing for the foundation's non-profit activities.

Differentiator

Problem solved

Functional benefit

Products and services

• IOIBD Operating Grants Program Competitive annual research grant program for clinical and basic science IBD projects, awarding up to €200,000 per project with annual deadline 01 September; for academic IBD researchers worldwide.
• IOIBD Travel Grants Program Annual travel grant program awarding up to €20,000 (two grants per year) for physicians and researchers visiting foreign IBD centers for 2–6 months of research or clinical experience; for early-career clinicians from countries with evolving IBD.
• IOIBD Clinical Experience Exchange Program One-year international training program placing gastroenterology physicians from developing nations at IOIBD member institutions (60% clinical, 40% research), funded at $60,000 per awardee per year by the Helmsley Charitable Trust.
• Empowering Women in IBD Leadership Program Nine-month intensive leadership program for female gastroenterologists with IBD focus, featuring monthly mentor sessions, three live group sessions at international GI events (UEGWeek 2025, ECCO 2026, DDW 2026), and dedicated business coaching; delivered with Pfizer support.
• IOIBD Publications and Consensus Guidelines Portfolio of scientific publications, consensus statements, and clinical guidelines produced by IOIBD task forces and cluster groups, published in peer-reviewed journals such as Gastroenterology, Gut, and JCC; serves the global IBD clinical and research community.
• IOIBD Annual General Meeting Annual in-person scientific meeting combining AGM business proceedings with satellite scientific sessions, sponsor/faculty dinners, senior member lectures, invited guest lectures, and full-day scientific sessions; rotated across global venues and attended by IOIBD members and invited guests.
• IOIBD Webinar Series Virtual educational webinar series covering IBD topics, including 7 COVID-19 and IBD webinars organized since March 2020 and taskforce guidelines; semi-annual virtual meetings feature grant presentations and cluster group project updates.

Quantifiable outcome

• STRIDE-II listed as Top 10 Most Cited Articles in Gastroenterology (2021)
• +1 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Others

• European Medicines Agency (EMA): Regulatory body whose IBD endpoint and trial-design expectations are shaped in part by IOIBD consensus outputs. Relevant as a downstream consumer and standard-setter in the IOIBD ecosystem.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): US federal funder of digestive disease research including IBD. Peer as an adjacent research-funder and standards-setter whose grant priorities influence IOIBD's agenda.
• Leona M. and Harry B. Helmsley Charitable Trust: Major private foundation funding IOIBD's Clinical Experience Exchange Program and broader IBD research grants. Relevant as an ecosystem peer and program sponsor rather than a competing organization.

Broad incumbents

• United European Gastroenterology (UEG): Pan-European umbrella for national GI societies that convenes UEG Week and influences IBD research priorities. Comparable as a multi-stakeholder GI convener with overlapping membership.
• American Gastroenterological Association (AGA): Broad gastroenterology society that publishes major IBD guidelines and runs large congresses (DDW). Overlaps with IOIBD in IBD guideline-setting and clinical trial design but covers the full GI spectrum.

Direct peers

• European Crohn's and Colitis Organisation (ECCO): Largest European organization devoted to IBD, with a broader membership base and major annual congress. ECCO and IOIBD operate in the same disease space, publish overlapping guidelines, and compete for industry funding and member mindshare.
• Crohn's & Colitis Foundation: US-based patient-advocacy and research nonprofit focused on Crohn's and ulcerative colitis. Direct peer in disease-specific funding, patient-education content, and industry partnership models.

Regional players

• British Society of Gastroenterology: UK national GI society publishing IBD guidelines and hosting education. Functions as a regional peer: overlapping scientific remit but UK-focused membership and footprint.
• Asia-Pacific Association of Gastroenterology (APAGE): Regional GI society covering fast-growing IBD populations in Asia-Pacific. Comparable to IOIBD in addressing emerging-market IBD but with a regional rather than global remit.
• European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN): European society for pediatric GI; intersects with IOIBD on pediatric-onset IBD guidance and overlaps in member institutions, but is regionally scoped and age-segmented.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ioibd1
• LinkedInlinkedin.com/company/ioibdofficial

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Organization For the Study of Inflammatory Bowel Disease